Works matching AU Semiond, Dorothée

Results: 12

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

Published in:

British Journal of Pharmacology, 2003, v. 138, n. 7, p. 1367, doi. 10.1038/sj.bjp.0705150

By:

Cisternino, Salvatore;
Bourasset, Fanchon;
Archimbaud, Yves;
Sémiond, Dorothée;
Sanderink, Gérard;
Scherrmann, Jean-Michel

Publication type:

Article

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Published in:

2021

By:

Mikhael, Joseph;
Belhadj-Merzoug, Karim;
Hulin, Cyrille;
Vincent, Laure;
Moreau, Philippe;
Gasparetto, Cristina;
Pour, Ludek;
Spicka, Ivan;
Vij, Ravi;
Zonder, Jeffrey;
Atanackovic, Djordje;
Gabrail, Nashat;
Martin, Thomas G.;
Perrot, Aurore;
Bensfia, Samira;
Weng, Qilong;
Brillac, Claire;
Semiond, Dorothée;
Macé, Sandrine;
Corzo, Kathryn P.

Publication type:

Letter to the Editor

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.

Published in:

2018

By:

Duran, George E.;
Derdau, Volker;
Weitz, Dietmar;
Philippe, Nicolas;
Blankenstein, Jörg;
Atzrodt, Jens;
Sémiond, Dorothée;
Gianolio, Diego A.;
Macé, Sandrine;
Sikic, Branimir I.

Publication type:

journal article

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 6, p. 1241, doi. 10.1007/s00280-014-2460-6

By:

Maison-Blanche, Pierre;
Dakhil, Shaker;
Baron, Ari;
Rottey, Sylvie;
Millard, Fred;
Daugaard, Gedske;
Machiels, Jean-Pascal;
Conkright, William;
Sharma, Sunil;
Soetekouw, Patricia;
Yachnin, Jeffrey;
Sengeløv, Lisa;
Veldhuizen, Peter;
Agarwala, Sanjiv;
Sémiond, Dorothée;
Chadjaa, Mustapha;
Shen, Liji;
Wade, James

Publication type:

Article

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 3, p. 681, doi. 10.1007/s00280-012-2058-9

By:

Ferron, Géraldine;
Dai, Yang;
Semiond, Dorothée

Publication type:

Article

Preclinical profile of cabazitaxel.

Published in:

Drug Design, Development & Therapy, 2014, v. 8, p. 1851, doi. 10.2147/DDDT.S64940

By:

Vrignaud, Patricia;
Semiond, Dorothée;
Benning, Veronique;
Beys, Eric;
Bouchard, Hervé;
Gupta, Sunil

Publication type:

Article

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.

Published in:

British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2052, doi. 10.1111/bcp.15123

By:

Thai, Hoai‐Thu;
Gaudel, Nadia;
Cerou, Marc;
Ayral, Geraldine;
Fau, Jean‐Baptiste;
Sebastien, Bernard;
van de Velde, Helgi;
Semiond, Dorothée;
Veyrat‐Follet, Christine

Publication type:

Article

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.

Published in:

2013

By:

Fumoleau, Pierre;
Trigo, Jose Manuel;
Isambert, Nicolas;
Sémiond, Dorothée;
Gupta, Sunil;
Campone, Mario

Publication type:

journal article

Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 12, p. 2087, doi. 10.1002/psp4.13206

By:

Pitoy, Antoine;
Desmée, Solène;
Riglet, François;
Thai, Hoai‐Thu;
Klippel, Zandra;
Semiond, Dorothée;
Veyrat‐Follet, Christine;
Bertrand, Julie

Publication type:

Article

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 12, p. 1846, doi. 10.1002/psp4.12947

By:

Thai, Hoai‐Thu;
Koiwai, Kimiko;
Shitara, Yoshihisa;
Kazama, Hirotaka;
Fau, Jean‐Baptiste;
Semiond, Dorothée;
Veyrat‐Follet, Christine

Publication type:

Article

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789

By:

Rachedi, Fatiha;
Koiwai, Kimiko;
Gaudel‐Dedieu, Nadia;
Sebastien, Bernard;
Thai, Hoai‐Thu;
Brillac, Claire;
Fau, Jean Baptiste;
Nguyen, Laurent;
van de Velde, Helgi;
Veyrat‐Follet, Christine;
Semiond, Dorothée

Publication type:

Article

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 928, doi. 10.1002/psp4.12666

By:

Koiwai, Kimiko;
El‐Cheikh, Raouf;
Thai, Hoai‐Thu;
Brillac, Claire;
Fau, Jean‐Baptiste;
Veyrat‐Follet, Christine;
Risse, Marie‐Laure;
van de Velde, Helgi;
Semiond, Dorothée;
Nguyen, Laurent

Publication type:

Article